Physician profile
Anna K Smith
NPI 1891193264
$2,749.93
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,966 · 2022: $709 · 2023: $53.92 · 2024: $21.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $75.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $75.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $311.64 | 2021-2023 | Imbruvica |
| Amgen INC. | $274.25 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $230.83 | 2021 | |
| Seagen INC. | $191.26 | 2021-2022 | |
| Beigene USA, INC. | $168.89 | 2021-2022 | |
| Genentech USA, INC. | $140.57 | 2021-2022 | |
| Janssen Biotech, INC. | $132.71 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $129.33 | 2021-2022 | |
| Daiichi Sankyo INC. | $129.28 | 2021 | |
| Pfizer INC. | $121.24 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $121.23 | 2021 | |
| Novartis Pharmaceuticals Corporation | $80.20 | 2021-2022 | |
| Acrotech Biopharma INC. | $76.80 | 2021 | |
| Servier Pharmaceuticals LLC | $60.29 | 2021-2023 | |
| Abbvie INC. | $49.29 | 2021-2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $47.63 | 2022 | |
| Lilly USA, LLC | $42.62 | 2021 | |
| Taiho Oncology, INC. | $36.75 | 2021 | |
| Genzyme Corporation | $36.22 | 2021 | |
| Aveo Pharmaceuticals, INC. | $36.14 | 2022 | |
| Eisai INC. | $34.32 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $28.96 | 2021-2022 | |
| Acceleron Pharma, INC. | $26.71 | 2021 | |
| Incyte Corporation | $26.28 | 2021 | |
| Amag Pharmaceuticals, INC. | $25.84 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.75 | 2021 | |
| Glaxosmithkline, LLC. | $19.06 | 2022 | |
| Astellas Pharma US INC | $18.80 | 2021 | |
| Array Biopharma INC | $18.35 | 2022 | |
| Adaptive Biotechnologies Corporation | $17.70 | 2022 | |
| Celgene Corporation | $16.30 | 2022 | |
| Tersera Therapeutics LLC | $16.27 | 2021 | |
| Sobi, INC | $14.30 | 2022 | |
| Kyowa Kirin, INC. | $13.77 | 2021 | |
| Dova Pharmaceuticals | $12.93 | 2021 | |
| Pharmacosmos Therapeutics INC. | $12.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $10.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.